DB07268 - JNK 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDB07268Cat. No.: HY-15737CAS No.: 929007-72-7分式: CHNO分量: 321.33作靶点: JNK作通路: MAPK/ERK Pathway储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 32 mg/mL (99.59 mM)* means soluble, but saturatio

2、n unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.1121 mL 15.5603 mL 31.1207 mL5 mM 0.6224 mL 3.1121 mL 6.2241 mL10 mM 0.3112 mL 1.5560 mL 3.1121 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件

3、，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (6.47 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (6.47 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVI

4、TY物活性 DB07268种有效的选择性 JNK1 抑制剂，IC50 值为 9 nM。IC50 & Target JNK1 CHK1 PAK4 AKT19 nM (IC50) 0.82 M (IC50) 5.5 M (IC50) 15 M (IC50)ERK225 M (IC50)体外研究 DB07268 (Compound 2b) also inhibits CHK1, PAK4, AKT1, and ERK2 with IC50s of 0.82 M, 5.5 M, 15 M, and 25 M, respectively 1.户使本产品发表的科研献 Cell Metab. 2019 Ju

5、l 2;30(1):157-173.e7See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Liu M, et al. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-